Overview

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Status:
Completed

Trial end date:
2013-10-29

Target enrollment:

Participant gender:

Summary

The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC) monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with a 10-year Framingham risk score of 10% or less.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Antibodies, Monoclonal
Evolocumab
Ezetimibe